biotechnology

Neuroscientists safely delivered a critical gene that improved vision for two patients with Leber congenital amaurosis.

What do 23andMe and Snapchat have in common? They both collect very personal information about their users. Do the benefits outweigh the risks?

Join a panel of experts as they discuss nanoparticle technology and key considerations for nanoparticle-based drug delivery.  

A biotech start-up teamed up with technology giants like Apple to continuously monitor people with Parkinson’s disease so that they could personalize their treatments in the clinic and the lab.

A new heart-on-a-chip gives scientists an up-close look at the beating human heart from the comfort of their lab benches.

Researchers are developing gene and cell therapies and prosthetics to help patients with blindness regain some vision. The first major prosthetic, the Argus II, was just discontinued. Where will the field go from here?

Membraneless droplet like organelles known as condensates are changing the way some scientists approach drug discovery.

Researchers no longer think that proteins blindly swim through the cytoplasm hoping to bump into one another. Instead, they intentionally aggregate with other biomolecules, forming membrane free, transient organelles called condensates.

The company plans to develop more specialized, antibody-based GPCR drugs to treat a myriad of diseases. They recruited a leader in overseeing successful clinical trials to get the job done.

Philip Yeske was an organic chemist for more than 20 years, but when his daughter died from the rare mitochondrial disorder Leigh Syndrome, he turned to connecting researchers, patients, and law makers to speed the discovery of treatments.